Agility will be the focus for Pharmaceutical and Medical Device Markets in 2016, says AMPLEXOR Life Sciences
The newly branded technology and services group warns that current market pressures demand a more holistic approach to global data handling.
Until the life sciences industry treats content management holistically, its ability to seize new market opportunities may be limited. So says Mark Evenepoel, group CEO of AMPLEXOR — the newly branded 360-degree content management corporation which brings together four technology and services powerhouses: euroscript, INFOTEHNA, ForeignExchange Translations, and Amplexor.
The combined group, rebranded as AMPLEXOR, will incorporate the AMPLEXOR Life Sciences brand as of today, and specializes in helping life sciences organizations accelerate their speed to market and enter new countries quickly. Its solutions and services expedite the creation and delivery of consistent, compliant and high-quality global content — both physical and digital — across all of a company’s target markets.
“Without a consistent, holistic approach to all forms of content, life sciences companies will never be truly agile,” Evenepoel warns. “The industry knows that, and I believe 2016 will be a turning point.”
His comments chime with research published by Gens & Associates (Next Generation Content Management “Pulse Survey”) in April. This suggests that life sciences organizations which manage their content at a holistic, pan-enterprise level derive greater value from their investments. All companies surveyed expect to move towards an enterprise-wide approach to content management governance within the next 2-5 years, as they strive to create a global authoritative source of content and information sharing.
Employing 1,600 people in 24 countries across four continents, AMPLEXOR Life Sciences has a 30+ year history of serving the biggest names in the pharmaceutical, medical device and biotechnology markets. It combines euroscript, a leading life sciences content management implementation specialist; INFOTEHNA, with its powerful content management platform and leading suite of life sciences solutions; ForeignExchange Translations, which provides expert professional medical translation, and Amplexor, a digital experience platform for managing content across web, mobile and social channels.
With its comprehensive technology solutions and professional services, spanning all forms of physical and digital content, AMPLEXOR Life Sciences is a leading, visionary one-stop-shop partner for life sciences companies. Its services include technology consultancy, implementation and management services; technical writing & linguistic services, and marketing asset creation and management.
“We’re very excited about the year ahead,” says Evenepoel, who before the rebranding was CEO of euroscript. “Pharma, medical device manufacturers and biotech firms face some significant challenges in 2016 as they align themselves with the latest regulatory reporting requirements while simultaneously racing competitors to bring out new products and enter new markets.
“There is so much going on for the sector right now. What we’re offering them is a lasting solution to one of the core challenges: managing all of the content and keeping it compliant and consistent wherever it appears ─ and ready to go as soon as it’s needed.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance